Shire PLC (NASDAQ:SHPG) Receives Consensus Recommendation of “Buy” from Brokerages
Shire PLC (NASDAQ:SHPG) has been given a consensus recommendation of “Buy” by the twenty-seven research firms that are covering the firm. Five analysts have rated the stock with a hold recommendation and twenty-two have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $234.43.
SHPG has been the subject of several research analyst reports. Goldman Sachs Group Inc. restated a “buy” rating on shares of Shire PLC in a report on Tuesday, June 28th. Jefferies Group restated a “buy” rating and issued a $262.00 price objective on shares of Shire PLC in a report on Wednesday, September 7th. TheStreet lowered Shire PLC to a “hold” rating in a report on Thursday, August 4th. JPMorgan Chase & Co. restated an “overweight” rating on shares of Shire PLC in a report on Monday, September 26th. Finally, Citigroup Inc. restated a “buy” rating on shares of Shire PLC in a report on Friday, July 15th.
Hedge funds have recently made changes to their positions in the stock. Jennison Associates LLC increased its stake in shares of Shire PLC by 13.2% in the second quarter. Jennison Associates LLC now owns 8,294,030 shares of the biopharmaceutical company’s stock valued at $1,526,765,000 after buying an additional 968,101 shares during the last quarter. FMR LLC increased its stake in shares of Shire PLC by 86.7% in the second quarter. FMR LLC now owns 2,663,506 shares of the biopharmaceutical company’s stock valued at $490,297,000 after buying an additional 1,237,100 shares during the last quarter. Lone Pine Capital LLC acquired a new stake in shares of Shire PLC during the second quarter valued at $465,566,000. Capital World Investors acquired a new stake in shares of Shire PLC during the second quarter valued at $285,568,000. Finally, Vanguard Group Inc. acquired a new stake in shares of Shire PLC during the second quarter valued at $278,421,000. Hedge funds and other institutional investors own 24.26% of the company’s stock.
Shares of Shire PLC (NASDAQ:SHPG) traded down 0.50% during mid-day trading on Tuesday, reaching $194.46. The company’s stock had a trading volume of 494,952 shares. The firm’s 50 day moving average is $196.04 and its 200-day moving average is $186.49. Shire PLC has a 52-week low of $147.60 and a 52-week high of $231.32. The company has a market capitalization of $57.92 billion, a PE ratio of 40.41 and a beta of 1.16.
Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.03 by $0.35. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. The company earned $2.43 million during the quarter, compared to analyst estimates of $2.28 billion. During the same quarter in the previous year, the firm posted $2.63 EPS. The firm’s quarterly revenue was up 55.9% on a year-over-year basis. Analysts forecast that Shire PLC will post $12.92 EPS for the current year.
The firm also recently announced a dividend, which will be paid on Friday, October 7th. Investors of record on Friday, September 9th will be paid a dividend of $0.139 per share. The ex-dividend date is Wednesday, September 7th. Shire PLC’s payout ratio is 15.63%.
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.